Immunometabolism refers to the modifications in immune cells' internal metabolic pathways that occur when they are activated. In recent years, a slew of discoveries has been made in the field of immunometabolism, which refers to changes in immune cells' internal metabolic pathways that modify their activity. Immunometabolism opens up new avenues for drug development in immune-related disorders. The ability to change the actions of macrophages in situ requires interconnection between certain metabolic components and immunological signalling pathways. Immunometabolism has emerged as a key regulator of both adaptive and innate immunity. It was evident from the beginning that metabolism and the immune system are intimately intertwined. Inflammatory cytokines were generated in obese adipose tissue, and these cytokines led to metabolic illness. Immunometabolism is a rapidly developing field of research, with a second research wave arising from cancer metabolism studies to explore the intrinsic metabolic pathways of immune cells themselves and how those pathways influence cell destiny and function. The field is driven by a few core ideas and goals.
Title : Diagnosis and differentiation of lyme disease and tick-borne relapsing fever borreliosis with multiplex line immunoblots
Ranjan Ramasamy, IDFISH Technology, United States
Title : Mast cell degranulation links anti-PEG IgE to anaphylaxis caused by PEGylated drugs and PEG-contained LNP/mRNA COVID vaccines
Zhaohua Zhou, Food and Drug Administration, United States
Title : Genetic factors influencing early immunity to SARS-CoV-2 in the upper respiratory tract
Ranjan Ramasamy, IDFISH Technology, United States
Title : Monoclonal antibodies efficacy in treatment of novel coronavirus infection (COVID-19) in children at risk of developing a severe course of the disease
Ismail Osmanov, Children's city clinical hospital, Russian Federation
Title : Considerations on MS animal modeling: Format of myelin immunogens used for experimental autoimmune encephalomyelitis model establishment may affect pharmacologic responses of anti-inflammatory drugs
WenQing Yang, Founder/Chief Scientific Officer, ClinBridge Biotech Corp., China
Title : Regulatory T cells with chimeric antigen receptors as treatment for autoimmunity
Matthias Hardtke Wolenski, Hannover Medical School, Germany